SCHEMBL27247391

SCHEMBL27247391

CC1(C(=O)NCc2cc3cc(O)c(Cl)cc3[nH]2)CC1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ RAB9A P51151 2/20 0.37
▸ NPC1 O15118 1/20 0.36
▸ MEN1 O00255 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ HSP90AA1 P07900 2/20 0.34
▸ HTT P42858 1/20 0.34
▸ CA12 O43570 2/20 0.33
▸ CA1 P00915 2/20 0.33
▸ CA2 P00918 2/20 0.33
▸ CA9 Q16790 2/20 0.33
▸ CYP19A1 P11511 1/20 0.33
▸ METTL3 Q86U44 4/20 0.33
▸ METTL14 Q9HCE5 4/20 0.33
▸ NR2E3 Q9Y5X4 1/20 0.32
▸ RHEB Q15382 1/20 0.32
▸ P2RX7 Q99572 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30920406 0.95 SMN1; SMN2 (0.43) SMN1; SMN2RAB9ANPC1MEN1LMNA
SCHEMBL27246735 0.95 SMN1; SMN2 (0.43) SMN1; SMN2RAB9ANPC1MEN1LMNA
SCHEMBL27247917 0.85 SMN1; SMN2 (0.38) SMN1; SMN2RAB9ANPC1MEN1LMNA
SCHEMBL27383517 0.84 SMN1; SMN2 (0.42) SMN1; SMN2RAB9ANPC1MEN1LMNA
SCHEMBL27247781 0.84 RAB9A (0.40) SMN1; SMN2RAB9ANPC1MEN1LMNA
SCHEMBL30920129 0.83 SMN1; SMN2 (0.41) SMN1; SMN2RAB9ANPC1MEN1LMNA
SCHEMBL27246888 0.83 SMN1; SMN2 (0.41) SMN1; SMN2RAB9ANPC1MEN1LMNA
SCHEMBL30920251 0.83 SMN1; SMN2 (0.38) SMN1; SMN2RAB9ANPC1MEN1LMNA
SCHEMBL30920444 0.83 RAB9A (0.43) SMN1; SMN2RAB9ANPC1CA12CA1
SCHEMBL30920136 0.83 RAB9A (0.38) SMN1; SMN2RAB9ANPC1MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF HERCULES CAPITAL, INC., AS AGENT 2024-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF SLC6A19, SLC2A9, SLC6A3 SMN1; SMN2 375/4885RAB9A 105/4885NPC1 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback